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Identity 
Other names: CPI-B; CST6; Cystatin-B; EPM1; PME; 
STFB; Stefin-B 




The stefin B gene is located on human chromosome 
21q22.3 and it contains 3 exons and 2 introns. The 
transcript length of stefin B mRNA is 294 bps. A novel 
variant, with retention of the entire intron 2 is 
transcribed from two exons with an ORF of 249 bp. It 
encodes a putative 9.0-kDa protein of 83 amino acids, 
including 57 identical to stefin B followed by 26 amino 
acids encoded by the intron 2 sequences. 
Protein 
 
Richardson diagram of stefin B structure: alpha-helixes are 
shown in red and beta-sheets in green (MEROPS: the 
peptidase database - I25.003: cystatin B). 
Description 
The cystatin superfamily comprises at least four 
families of closely related proteins, such as stefins 
(family I), cystatins (family II), kininogens (family III), 
and various structurally related but noninhibitory 
proteins of family IV. A significant structural 
difference between stefins and cystatins is the signal 
peptide, which is responsible for extracellular targeting 
of cystatins, whereas stefins lack this peptide and have 
been reported as intracellular inhibitors. Human stefin 
B is a single chain protein consisting of 98 amino acid 
residues, with a molecular mass of 11,175 kDa. Stefin 
B is a neutral protein with pI values between 5.9 - 6.5 
and is able to form a dimmer stabilized by noncovalent 
forces. Like other members of the cystatin superfamily, 
stefin B is reversible and competitive inhibitor of
cysteine proteases, particularly cathepsin L and 
cathepsin S with Ki values in the picomolar range 
whereas cathepsin B inhibition is weaker (Ki 10-7M). 
Expression 
Stefin B is widely distributed among different cell 
types and tissues. Although it lacks an export signal 
sequence and is generally thought to function 
intracellularly, it has also been found in extracellular 
fluid. 
Function 
Stefin B is thought to play a role in protecting cytosolic 
and cytoskeleton proteins against the cysteine proteases 
accidentally released from lysosomes. Besides protease 
inactivation stefin B could bind other proteins in a 
multiprotein complex which might contribute to the 
disease in patients with progressive myoclonus 
epilepsy. Decreased levels of stefin B mRNA were 
detected in patients with progressive myoclonus 
epilepsy and associated with excessive activity of 
cathepsin B. Moreover, stefin B may be important in  
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the control of osteoclasts bone resorption. It inhibits 
bone resorption by down-regulating intracellular 
cathepsin K activity. On the other hand stefin B 
protected osteoclasts from experimentally induced 
apoptosis, promoting cell survival in the nervous 
system. 
Homology 
Human stefin B exhibit a high degree of homology to 
other cysteine protease inhibitors of the cystatin 
superfamily which includes human stefin A and the 
homologues in other species. It is 79% identical with 




Eight mutations in the stefin B gene have been report d 
to associate with an autosomal recessive 
neurodegenerative disorder, progressive myoclonus 
epilepsy of Unverricht-Lundborg type (EPM1). Most of 
the disease alleles harbour an unstable expansion of at 
least 30 copies of a normally polymorphic 12-
nucleotide, dodecamer repeat located in the promoter 
region of the stefin B gene. Three reported EPM1 
mutations affect splice sites, two result in amino-acid 
changes and two predict truncated proteins either 





Higher levels of stefin B in tumours have been 
determined in lung, breast, head and neck and prostate 
cancer as well as in murine lymphosarcomas, 
hepatomas and Lewis lung carcinomas. These higher 
levels, up to a certain level, may counter-balance the 
excessive activity of cysteine cathepsins, associated 
with matrix remodelling resulting in the progression f 
the disease. On the other hand, high cytosolic levels of 
stefins may be relevant for regulation of apoptosis, 
when initiated via lysosomal cell death pathway 
inhibiting cathepsin B, which was proposed as a 
dominant execution protease in the lysosomal apoptotic 
pathways, induced in a variety of tumour cells by 
tumour necrosis factor alpha (TNF-alpha). In some 
studies lower levels of stefins in tumours have been 
reported. Lower mRNA levels of stefin B have been 
reported in breast and esophagus tumours as compared 
to adjacent control tissues. 
Although stefins are cytosolic proteins, they have lso 
been detected in body fluids of cancer patients. Stefin B 
has been detected in ascitic fluid from patients with 
ovarian carcinoma and in bronhoalveolar fluid of lung 
cancer patients.  
Diagnosis: The poor survival rate of hepatocellular 
carcinoma is in part due to the inability to diagnose 
patients at an early stage. Stefin B is specifically 
overexpressed in most hepatocellular carcinoma and is 
also elevated in the serum of a large proportion of 
hepatocellular carcinoma patients. Stefin B may be a 
useful marker for diagnosing patients with 
hepatocellular carcinoma with a high sensitivity. 
Prognosis 
Higher levels of stefin B in tumour tissues have ben 
shown to correlate with a favourable prognosis of 
cancer patients. A significant prognostic value of stefin 
B was determined in patients with lung and head and 
neck cancer. On the other hand, animal model with 
excluded expression of stefin B did not support its 
suppressive function in cancer. A significantly lower 
metastatic spread was detected in stefin B knock-out 
mice than in wild-type animals. Similarly, higher lvels 
of stefin B in body fluids have been associated with a 
poor prognosis of cancer patients. Alterations in 
secretion may result in higher extracellular and lower 
intracellular levels of stefins and, therefore, a reverse 
correlation with patient' survival is to be expected. 
Oncogenesis 
Increased levels of cysteine protease activity, not being 
balanced by a corresponding increase of cysteine 
protease inhibitors are associated with progression of 
malignant disease and poor patient's prognosis. 
Enhanced expression of stefin B would be expected to 
diminish the tumour-associated proteolytic activity and 
indeed, there is evidence of a suppressive role of stefin 
B in various cancer types. 
Progressive myoclonus epilepsy 
Disease 
The progressive myoclonus epilepsy of the Unverricht-
Lundborg type (EPM1) is an autosomal recessive 
disease characterized by progressive myoclonic jerks 
and decline in cognition. Genetic linkage studies, 
suggest the involvement of the stefin B gene. A 
decreased amount of stefin B mRNA is a common 
finding in EPM1 patients and it may be due to: 1) a 
mutation in the promoter region causing a decrease in 
the rate of transcription of the gene or 2) mutations f 
the coding region/splice sites that may inhibit 
translation or diminish the half-life of the transcript 
and/or of the protein. The availability of a stefin B 
knock-out mouse as a model for the disease has 
allowed identification of the presence of severe 
apoptotic damage to the cerebellar granule cells. This 
observation combined with the anti-protease functio 
of stefin B protein has suggested that it  
may have an anti-apoptotic function in the cerebellum. 
It was shown that a number of proteins (manly proteins 
that are involved in the regulation of cytoskeletal 
functions) that are not proteases can interact 
specifically with stefin B, forming a multiprotein  
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complex. The first hypothesis is that stefin B may be 
active as antiprotease, protecting the complex against 
the attack of proteases. An alternative hypothesis is that 
stefin B may bind to the interacting proteins modifying 
the structure, thus allowing the correct formation of the 
complex. A further hypothesis is the sequestration of 
stefin B by the multiprotein complex, thus impeding ts 
interaction with cathepsins. 
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